Treatment with a substance p receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early parkinson's disease

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Thornton, Emma ^a   Vink, Robert ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

L 333060; N ACETYLTRYPTOPHAN; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROTOXIN; OXIDOPAMINE; SUBSTANCE P; SUBSTANCE P ANTAGONIST; UNCLASSIFIED DRUG; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE; N-ACETYLTRYPTOPHAN; NEUROKININ 1 RECEPTOR; NEUROPROTECTIVE AGENT; PIPERIDINE DERIVATIVE; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BLOOD NERVE BARRIER; CELL ACTIVATION; CELL LOSS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; IN VIVO STUDY; MALE; MICROGLIA; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; ROTAROD TEST; SUBSTANTIA NIGRA; TREATMENT OUTCOME; ANIMAL; CELLS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; INFLAMMATION; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD-BRAIN BARRIER; CELLS; DOPAMINERGIC NEURONS; INFLAMMATION; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROKININ-1; ROTAROD PERFORMANCE TEST; SUBSTANCE P; SUBSTANTIA NIGRA; TRYPTOPHAN;

EID: 84859219632     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034138     Document Type: Article

References (56)

1. Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP, (2008) Epidemiology of Parkinson's disease. J Neurol 255: 18-32.
2. Chen L-W, Yung KKL, Chan YS, (2004) Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease. Current Drug Targets 5: 1-10.
3. Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, et al. (2003) Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci 18: 2731-2742.
4. McGeer PL, McGeer EG, (2008) Glial reactions in Parkinson's disease. Mov Disord 23: 474-483.
5. Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, et al. (2006) Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res 6: 261-281.
6. Takagi S, Hayakawa N, Kimoto H, Kato H, Araki T, (2007) Damage to oligodendrocytes in the striatum after MPTP neurotoxicity in mice. J Neural Transm 114: 1553-1557.
7. Chung YC, Ko HW, Bok E, Park ES, Huh SH, et al. (2010) The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep 43: 225-232.
8. Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de Vries R, et al. (2008) Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm 115: 1001-1009.
9. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, et al. (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57: 176-179.
10. Ionov ID, (2008) Self-amplification of nigral degeneration in Parkinson's disease: a hypothesis. Int J Neurosci 118: 1763-1780.
11. Rite I, Machado A, Cano J, Venero JL, (2007) Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J Neurochem 101: 1567-1582.
12. Harrison S, Geppetti P, (2001) Review: Substance P. The International J Biochem Cell Biol 33: 555-576.
13. Levesque M, Wallman MJ, Parent R, Sik A, Parent A, (2007) Neurokinin-1 and neurokinin-3 receptors in primate substantia nigra. Neurosci Res 57: 362-371.
14. Reid MS, Herrera-Marschitz M, Hokfelt T, Lindefors N, Persson H, et al. (1990) Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms. Exp Brain Res 82: 293-303.
15. Thornton E, Tran TT, Vink R, (2010) A substance P mediated pathway contributes to 6-hydroxydopamine induced cell death. Neurosci Lett 481: 64-67.
16. De Ceballos ML, Lopez-Lozano JJ, (1999) Subgroups of parkinsonian patients differentiated by pertidergic immunostaining of caudate nuclues biopsies. Peptides 20: 249-257.
17. Mauborgne A, Javoy-Agid F, Legrand JC, Agid Y, Cesselin F, (1983) Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains. Brain Res 268: 167-170.
18. Nisbet AP, Foster OJ, Kingsbury A, Eve DJ, Daniel SE, et al. (1995) Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 66: 361-376.
19. Sivam SP, (1991) Dopamine dependent decrease in enkephalin and substance P levels in basal ganglia regions of postmortem Parkinsonian brains. Neuropeptides 18: 201-207.
20. Tenovuo O, Rinne UK, Viljanen MK, (1984) Substance P immunoreactivity in the post-mortem parkinsonian brain. Brain Res 303: 113-116.
21. Fernandez A, de Ceballos ML, Jenner P, Marsden CD, (1994) Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients. Neuroscience 61: 73-79.
22. Bannon MJ, Brownschidle LA, Tian Y, Whitty CJ, Poosch MS, et al. (1995) Neurokinin-3 receptors modulate dopamine cell function and alter the effects of 6-hydroxydopamine. Brain Res 695: 19-24.
23. Schwarting RK, Huston JP, (1996) Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol 49: 215-266.
24. Deumens R, Blokland A, Prickaerts J, (2002) Modeling Parkinson's disease in rats: an evaulation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175: 303-324.
25. Bevan MD, Smith AD, Bolam JP, (1996) The substantia nigra as a site of synaptic integration of functionally diverse information arising from the ventral pallidum and the globus pallidus in the rat. Neuroscience 75: 5-12.
26. Lin RC, (1995) Reactive astrocytes express substance-P immunoreactivity in the adult forebrain after injury. Neuroreport 7: 310-312.
27. Nimmo AJ, Cernak I, Heath DL, Hu X, Bennett CJ, et al. (2004) Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats. Neuropeptides 38: 40-47.
28. Vink R, van den Heuvel C, (2010) Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury. Neurotherapeutics 7: 74-80.
29. Turner RJ, Helps SC, Thornton E, Vink R, (2011) A substance P antagonist improves outcome when administered 4 hours after onset of reversible cerebral ischemia. Brain Res 1393: 84-90.
30. Donkin JJ, Nimmo AJ, Cernak I, Blumbergs PC, Vink R, (2009) Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury. J Cereb Blood Flow Metab 29: 1388-1398.
31. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, et al. (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119: 182-192.
32. Ji KA, Eu MY, Kang SH, Gwag BJ, Jou I, et al. (2008) Differential neutrophil infiltration contributes to regional differences in brain inflammation in the substantia nigra pars compacta and cortex. Glia 56: 1039-1047.
33. Carson MJ, Thrash JC, Walters B, (2006) The cellular response in neuroinflammation: The role of leukocytes, microglia and astroctyes in neuronal death and survival. Clin Neurosci Res 6: 237-245.
34. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, et al. (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 81: 1285-1297.
35. Teismann P, Schulz JB, (2004) Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res 318: 149-161.
36. Liu B, Hong JS, (2003) Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304: 1-7.
37. Rock RB, Peterson PK, (2006) Microglia as a pharmacological target in infectious and inflammatory diseases of the brain. J Neuroimmune Pharmacol 1: 117-126.
38. Shults CW, (2004) Mitochondrial dysfunction and possible treatments in Parkinson's disease-a review. Mitochondrion 4: 641-648.
39. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, et al. (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65: 135-172.
40. Chauhan VS, Sterka DG Jr, Gray DL, Bost KL, Marriott I, (2008) Neurogenic exacerbation of microglial and astrocyte responses to Neisseria meningitidis and Borrelia burgdorferi. J Immunol 180: 8241-8249.
41. Marriott I, (2004) The role of tachykinins in central nervous system inflammatory responses. Front Biosci 9: 2153-2165.
42. Block ML, Li G, Qin L, Wu X, Pei Z, et al. (2006) Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin. Faseb J 20: 251-258.
43. Wojtera M, Sikorska B, Sobow T, Liberski PP, (2005) Microglial cells in neurodegenerative disorders. Folia Neuropathol 43: 311-321.
44. Mantyh PW, Johnson DJ, Boehmer CG, Catton MD, Vinters HV, et al. (1989) Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. Proc Natl Acad Sci USA 86: 5193-5197.
45. Brahmachari S, Fung YK, Pahan K, (2006) Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide. J Neurosci 26: 4930-4939.
46. Hirsch EC, (2000) Glial cells and Parkinson's disease. J Neurol 247 (Suppl 2): II58-62.
47. Rodriguez MC, Obeso JA, Olanow C, (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 44: S178-188.
48. Beal MF, (1992) Mechanisms of excitotoxicity in neurologic disease. Faseb J 6: 3338-3344.
49. Marti M, Manzalini M, Fantin M, BianchiC, Della Corte L, et al. (2005) Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoiong neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine. J Neurochem 93: 195-205.
50. Paxinos G, Watson C, (1998) The Rat Brain Stereotaxic Coordinates San Diego Academic Press.
51. Bishop C, Walker PD, (2004) Intranigral antagonism of neurokinin 1 and 3 receptors reduces intrastriatal dopamine D1 receptor-stimulated locomotion in the rat. Brain Res 1023: 126-133.
52. Ukai M, Mori E, Kameyama T, (1995) Effects of centrally administered neuropeptides on discriminative stimulus properties of cocaine in the rat. Pharmacol Biochem Behav 51: 705-708.
53. Lee CS, Sauer H, Bjorklund A, (1996) Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience 72: 641-653.
54. Ogura T, Ogata M, Akita H, Jitsuki S, Akiba L, et al. (2005) Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease. Neurosci Res 51: 299-308.
55. Hamm RJ, Pike BR, O'Dell DM, Lyeth BG, Jenkins LW, (1994) The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma 11: 187-196.
56. Helps SC, Thornton E, Kleinig TJ, Manavis J, Vink R, (2012) Automatic non-subjective estimation of antigen content visualused by immunohistochemistry using colour deconvolution. Appl Immunohistochem Molec Morph 20: 82-90.